|Awarded On||August 18, 2021|
|Title||Cytokine factories for the treatment of mesothelioma|
|Award Mechanism||High Impact/High Risk|
|Principal Investigator/Program Director||Omid Veiseh|
|Cancer Sites||Lung and Bronchus|
*Pending contract negotiation
Malignant Pleural Mesothelioma (MPM) is a highly aggressive pleural malignancy that is lethal in essentially all cases. Few effective treatments exist and 5-year mortality is >90%. Cytokine therapy has tremendous potential for cancer patients, but serious technological limitations remain. The inherent instability of recombinant cytokines is one of the key obstacles to clinical application. The instability necessitates high/frequent doses which also cause severe toxicities and patients are often forced to stop treatments. New drug delivery platforms which provide spatial and temporal control over delivery of immunotherapy payloads can significantly improve therapy outcomes while reducing t...